Original Article: bit.ly/1BRH2l1
SEATTLE — A project integrating time-limited pre-exposure prophylaxis along with ART among high-risk, serodiscordant couples demonstrated an observed HIV incidence of less than 0.5% per year, according to data presented at CROI 2015.
“Developing effective strategies to deliver ART and PrEP to couples is a priority,” Jared Baeten, MD, PhD, professor at the University of Washington, said during his presentation. “Approaches that integrate ART and PrEP may have maximal benefits, since neither alone eliminates HIV risk.”
Baeten and colleagues conducted the Partners Demonstration Project, an open-label, prospective, interventional study conducted at four clinical care sites in Africa. Heterosexual serodiscordant couples were enrolled, and the infected partner received ART regardless of CD4 count, and the uninfected partner received Truvada (tenofovir/emtricitabine, Gilead Sciences) PrEP until the infected partner had been on ART for 6 months, allowing time for the partner to achieve viral suppression. None of the enrolled couples participated in the Partners PrEP study. The couples were followed at 1 month, and then quarterly for up to 24 months.
Full text of article available at link below: bit.ly/1BRH2l1